Journal of Clinical Virology最新文献

{"title":"Clinical and molecular characteristics of the 2022 Enterovirus-D68 outbreak among hospitalized children, Ohio, USA","authors":"Raquel Giacomelli Cao ,&nbsp;Asuncion Mejias ,&nbsp;Amy L. Leber ,&nbsp;Huanyu Wang","doi":"10.1016/j.jcv.2023.105618","DOIUrl":"10.1016/j.jcv.2023.105618","url":null,"abstract":"<div><h3>Background</h3><p>Enterovirus-D68 (EV-D68) has appeared biennially in the United States following the 2014 outbreak. It has gained epidemiologic and clinical relevance and was identified as an important pathogen associated with severe respiratory and central nervous system diseases. We aim to describe the clinical and molecular characteristics of the post-pandemic 2022 Enterovirus-D68 outbreak in children evaluated in a tertiary pediatric hospital in Columbus, Ohio.</p></div><div><h3>Methods</h3><p>EV-D68 RT-PCR was performed on nasopharyngeal specimens collected during Jun—Nov 2022 from children (&lt;18 years), identified by 1) physician-order or 2) random selection of 10–15 specimens weekly that were Rhinovirus/Enterovirus-positive by physician-ordered respiratory virus panel. Patients who tested positive for EV-D68 were identified and clinical data and outcomes were analyzed. Partial viral VP1 region was sequenced and characterized.</p></div><div><h3>Results</h3><p>Forty-four children positive for EV-D68 were identified, among which 88.6 % of patients presented with respiratory symptoms and 61.4 % required PICU admission. Two patients presented with AFM that was attributed to EV-D68. EV-D68 sequences from 2022 clustered within the B3 subclade.</p></div><div><h3>Conclusions</h3><p>A significant proportion of children identified with EV-D68 during the 2022 outbreak had respiratory compromise requiring PICU admission. As the virus continues evolving, it is important to monitor the activity of EV-D68, characterizing these strains clinically and genetically, which will help to understand the viral pathogenicity and virulence.</p></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"169 ","pages":"Article 105618"},"PeriodicalIF":8.8,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135455063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arbovirus surveillance in pregnant women in north-central Nigeria, 2019–2022","authors":"Jerry Ogwuche ,&nbsp;Charlotte Ajeong Chang ,&nbsp;Olukemi Ige ,&nbsp;Atiene S. Sagay ,&nbsp;Beth Chaplin ,&nbsp;Makshwar L. Kahansim ,&nbsp;Michael Paul ,&nbsp;Michael Elujoba ,&nbsp;Godwin Imade ,&nbsp;Georgenia Kweashi ,&nbsp;Yu-Ching Dai ,&nbsp;Szu-Chia Hsieh ,&nbsp;Wei-Kung Wang ,&nbsp;Donald J. Hamel ,&nbsp;Phyllis J. Kanki","doi":"10.1016/j.jcv.2023.105616","DOIUrl":"10.1016/j.jcv.2023.105616","url":null,"abstract":"<div><h3>Background</h3><p>The adverse impact of Zika (ZIKV), dengue (DENV), and chikungunya (CHIKV) virus infection in pregnancy has been recognized in Latin America and Asia but is not well studied in Africa. Although originally discovered in sub-Saharan Africa the non-specific clinical presentation of arbovirus infection may have hampered our detection of adverse clinical outcomes and outbreak.</p></div><div><h3>Objective</h3><p>This prospective study of arbovirus infection in pregnant women in north-central Nigeria sought to characterize the prevalence of acute arbovirus infection and determine the impact on pregnancy and infant outcomes.</p></div><div><h3>Methods</h3><p>In Nigeria, we screened 1006 pregnant women for ZIKV, DENV and CHIKV IgM/IgG by rapid test (2019–2022). Women with acute infection were recruited for prospective study and infants were examined for any abnormalities from delivery through six months. A subset of rapid test-reactive samples were confirmed using virus-specific ELISAs and neutralization assays.</p></div><div><h3>Results</h3><p>The prevalence of acute infection (IgM+) was 3.8 %, 9.9 % and 11.8 % for ZIKV, DENV and CHIKV, respectively; co-infections represented 24.5 % of all infections. The prevalence in asymptomatic women was twice the level of symptomatic infection. We found a significant association between acute maternal ZIKV/DENV/CHIKV infection and any gross abnormal birth outcome (<em>p</em> = 0.014).</p></div><div><h3>Conclusions</h3><p>Over three rainy seasons, regular acute infection with ZIKV, DENV, and CHIKV was observed with significantly higher rates in pregnant women without symptoms. The potential association arbovirus infection with abnormal birth outcome warrants further prospective study to ascertain the clinical significance of these endemic arboviruses in Africa.</p></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"169 ","pages":"Article 105616"},"PeriodicalIF":8.8,"publicationDate":"2023-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1386653223002391/pdfft?md5=203673465012f24d708677b4b78368b1&pid=1-s2.0-S1386653223002391-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72014422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Opt-out testing for hepatitis B and C infections in adults attending the emergency department of a large London teaching hospital","authors":"Jingwei Zeng ,&nbsp;Douglas Macdonald ,&nbsp;Russell Durkin ,&nbsp;Dianne Irish ,&nbsp;Jennifer Hart ,&nbsp;Tanzina Haque","doi":"10.1016/j.jcv.2023.105615","DOIUrl":"10.1016/j.jcv.2023.105615","url":null,"abstract":"<div><h3>Background</h3><p>The National Health Service (NHS) in England commissioned opt-out testing in London Emergency Departments (ED) in April 2022 to allow early identification and management of hepatitis B (HBV) and hepatitis C virus (HCV) infection in patients unaware of their infection status.</p></div><div><h3>Methods</h3><p>All adults over the age of 16 undergoing blood tests in the ED at the Royal Free Hospital were tested for HBV surface antigen and anti-HCV IgG unless they opted out. Data was collected between the 12th of April and 22nd of August 2022.</p></div><div><h3>Outcome</h3><p>Of 11,215 patients tested for HCV, 164 patients were found to be anti-HCV IgG positive, giving a seroprevalence rate of 1.46 %. 52 of the anti-HCV IgG positive patients did not have any previous HCV serology result. 23 of the anti-HCV IgG positive patients were also HCV RNA positive giving an RNA seroprevalence of 0.21 %, and 17 of those were new diagnoses of HCV viraemia. For HBV testing, 82 (0.73 %) out of 11,192 patients tested were found to be HBsAg positive, including one patient who presented acutely with a positive HBV core IgM. 39 of the HBsAg positive patients were previously unknown to us; of these, 9 had an HBV viral load of more than 2000 IU/mL, including 3 patients with positive HBV e antigen and one patient with hepatitis D virus co-infection.</p></div><div><h3>Conclusion</h3><p>Opt-out screening of HBV and HCV in ED is effective at identifying patients with previously undiagnosed viral hepatitis infection and providing an opportunity to engage them in specialist care.</p></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"169 ","pages":"Article 105615"},"PeriodicalIF":8.8,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S138665322300238X/pdfft?md5=9dd31f837231196d695bdf4b6e88ed06&pid=1-s2.0-S138665322300238X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72209607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of two serological screening strategies for cytomegalovirus primary infection in the first trimester of pregnancy","authors":"Jacques Fourgeaud ,&nbsp;Chiêu-Ân Nguyen ,&nbsp;Tiffany Guilleminot ,&nbsp;Yves Ville ,&nbsp;Marianne Leruez-Ville","doi":"10.1016/j.jcv.2023.105614","DOIUrl":"https://doi.org/10.1016/j.jcv.2023.105614","url":null,"abstract":"<div><h3>Introduction</h3><p>CMV serology screening in the first trimester pregnancy is based on IgG and IgM testing followed by IgG avidity in cases with positive IgM. However, the sensitivity of this strategy to diagnose maternal primary infection has been questioned. The objective of the study was to compare this strategy 1 with a strategy 2 consisting of running avidity test on all samples with positive IgG (ignoring IgM results) using fully automated current generation CMV IgG, IgM and IgG avidity assays.</p></div><div><h3>Population and methods</h3><p>1516 consecutive pregnant women between 12 and 14 weeks were screened in one maternity. Strategy 1 was done prospectively with LIAISON® CMV IgG II and LIAISON® CMV IgM II, followed by LIAISON® CMV IgG Avidity II and VIDAS® CMV IgG avidity II testing in cases with positive or equivocal IgM. Strategy 2 was done retrospectively on the same population and consisted of running avidity with the LIAISON® CMV IgG Avidity II in all samples with positive IgG.</p></div><div><h3>Results</h3><p>The sensitivity to diagnose a confirmed or a possible maternal primary infection in the first trimester was 91.6 % and 83 % for strategy 1 and 2 respectively (<em>p</em> &gt; 0.99). Strategy 1 missed one possible primary infection and strategy 2 missed 2 confirmed primary infection. Inconclusive results happened in 0 and 0.7 % of samples with strategy 1 and 2 respectively.</p></div><div><h3>Conclusion</h3><p>This study suggests that strategy 1 has better sensitivity and practicability than strategy 2. However, to achieve a good performance with strategy 1, using highly sensitive IgM assay is mandatory.</p></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"169 ","pages":"Article 105614"},"PeriodicalIF":8.8,"publicationDate":"2023-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91963109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular point-of-care devices for the diagnosis of infectious diseases in resource-limited settings – A review of the current landscape, technical challenges, and clinical impact","authors":"Kenneth Gavina ,&nbsp;Lauren C. Franco ,&nbsp;Haseeba Khan ,&nbsp;John-Paul Lavik ,&nbsp;Ryan F. Relich","doi":"10.1016/j.jcv.2023.105613","DOIUrl":"10.1016/j.jcv.2023.105613","url":null,"abstract":"<div><p>Molecular point-of-care (POC) tests offer high sensitivity, rapid turnaround times, relative ease of use, and the convenience of laboratory-grade testing in the absence of formal laboratory spaces and equipment, making them appealing options for infectious disease diagnosis in resource-limited settings. In this review, we discuss the role and potential of molecular POC tests in resource-limited settings and their associated logistical challenges. We discuss U.S. Food and Drug Administration approval, Clinical Laboratory Improvement Amendments complexity levels, and the REASSURED criteria as a starting point for assessing options currently available inside and outside of the United States. We then present POC tests currently in research and development phases that have potential for commercialization and implementation in limited-resource settings. Finally, we review published studies that have assessed the clinical impact of molecular POC testing in limited- and moderate-resource settings.</p></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"169 ","pages":"Article 105613"},"PeriodicalIF":8.8,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49690778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Viral pathogen detection using multiplex gastrointestinal molecular panels: The pros and cons of viral target inclusion","authors":"Eleanor A. Powell ,&nbsp;D. Jane Hata ,&nbsp;Meghan W. Starolis","doi":"10.1016/j.jcv.2023.105612","DOIUrl":"10.1016/j.jcv.2023.105612","url":null,"abstract":"<div><p>Diagnosis of gastrointestinal infections has been revolutionized by the development of in vitro diagnostic (IVD) multiplex molecular panels for the detection of viral nucleic acids. In addition to a high degree of accuracy, these panels are commercially available and relatively simple to perform in the clinical laboratory. However, use of these panels must be carefully considered owing to the laboratory costs of the test, limited reimbursement, and potential for overuse. In this review from the Pan American Society for Clinical Virology, we focus on the viral components of GI multiplex panels (GIPs), presenting a brief overview of pathogens included on most panels and a discussion of advantages and challenges of the inclusion of viral targets on GIPs that should be considered before implementation in the clinical laboratory.</p></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"169 ","pages":"Article 105612"},"PeriodicalIF":8.8,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49690779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing COVID-19 and influenza: Epidemiology, clinical characteristics, outcomes and mortality in the ICU","authors":"Quentin Pangot ,&nbsp;François Labaste ,&nbsp;Vincent Pey ,&nbsp;Chloé Médrano ,&nbsp;Adam Tuijnman ,&nbsp;Stéphanie Ruiz ,&nbsp;Jean-Marie Conil ,&nbsp;Vincent Minville ,&nbsp;Fanny Vardon-Bounes","doi":"10.1016/j.jcv.2023.105600","DOIUrl":"10.1016/j.jcv.2023.105600","url":null,"abstract":"<div><h3>Rationale</h3><p>Several authors have compared COVID-19 infection with influenza in the ICU.</p></div><div><h3>Objective</h3><p>This study aimed to compare the baseline clinical profiles, care procedures, and mortality outcomes of patients admitted to the intensive care unit, categorized by infection status (Influenza vs. COVID-19).</p></div><div><h3>Methods</h3><p>Retrospective observational study. Data were extracted from the Toulouse University Hospital from March 2014 to March 2021. To compare survival curves, we plotted the survival at Day-90 using the Kaplan-Meier curve and conducted a log-rank test. Additionally, we performed propensity score matching to adjust for confounding factors between the COVID-19 and influenza groups. Furthermore, we use the CART model for multivariate analysis.</p></div><div><h3>Results</h3><p>The study included 363 patients admitted to the ICU due to severe viral pneumonia: 152 patients (41.9 %) with influenza and 211 patients (58.1 %) with COVID-19. COVID-19 patients exhibited a higher prevalence of cardiovascular risk factors, whereas influenza patients had significantly higher severity scores (SOFA: 10 [6–12] vs. 6 [3–9], <em>p</em>&lt;0.01 and SAPS II: 51 [35–67] vs. 37 [29–50], <em>p</em>&lt;0.001). Overall mortality rates were comparable between the two groups (27.6 % (<em>n</em> = 42) in the influenza group vs. 21.8 % (<em>n</em> = 46) in the COVID-19 group, <em>p</em>=NS). Mechanical ventilation was more commonly employed in the influenza group (76.3 % (<em>n</em> = 116) vs. 59.7 % (<em>n</em> = 126), <em>p</em>&lt;0.001); however, COVID-19 patients required longer durations of mechanical ventilation (18 [9–29] days vs. 13 [5–24] days, <em>p</em>&lt;0.006) and longer hospital stays (23 [13–34] days vs. 18.5 [9–34.5] days, <em>p</em> = 0.009). The CART analysis revealed that the use of extra renal replacement therapy was the most influential prognostic factor in the influenza group, while the PaO2/FiO2-PEEP ratio played a significant role in the COVID-19 group.</p></div><div><h3>Conclusions</h3><p>Despite differences in clinical presentation and prognostic factors, the mortality rates at 90 days, after adjusting for confounding factors, were similar between COVID-19 and influenza patients.</p></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"169 ","pages":"Article 105600"},"PeriodicalIF":8.8,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72209606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FDA trial regulation of laboratory developed tests (LDTs): An academic medical center's experience with Mpox in-house testing","authors":"JR Caldera,&nbsp;Hannah K. Gray,&nbsp;Omai B. Garner,&nbsp;Shangxin Yang","doi":"10.1016/j.jcv.2023.105611","DOIUrl":"10.1016/j.jcv.2023.105611","url":null,"abstract":"<div><p>The 2022 mpox outbreak presented a familiar challenge to clinical laboratories. Accordingly, our institution was able to swiftly implement in-house mpox testing to meet the imminent diagnostic needs of the public health emergency. While the FDA authorized laboratory-developed tests (LDTs) for lesion specimens, however, it restricted the testing of rectal swabs despite mounting evidence of its clinical utility. Notably, within the short timeframe when rectal testing was available, we identified a high-risk patient without apparent lesions who tested monleypox-positive only by our in-house rectal swab assay. In order for our institution to continue testing non-lesion samples, The FDA required a separate Emergency Use Authorization (EUA) application that demanded additional resource-costly validation studies despite utilizing the same testing platform as lesion samples. Here, we provide a brief review of the history, current status, and legal scope surrounding LDT validations, with an in-depth comparison of the technical requirements by CLIA, CAP and the FDA. Importantly, we provide our experience with the mpox EUA submission process to serve as context for the challenges that may be imposed by the new FDA regulations. We hope that our experience will offer a valuable perspective that promotes constructive discourse towards addressing the imperative to offer high-quality laboratory diagnostics without compromising on the need of the medical laboratory community to provide effective patient care.</p></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"169 ","pages":"Article 105611"},"PeriodicalIF":8.8,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49690777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of chronic joint pain after Chikungunya virus infection in the INOVACHIK prospective cohort study","authors":"Ezequias B. Martins ,&nbsp;Marcel S.B. Quintana ,&nbsp;Michele F.B. Silva ,&nbsp;Fernanda de Bruycker-Nogueira ,&nbsp;Isabella C.V. Moraes ,&nbsp;Cintia D.S. Rodrigues ,&nbsp;Carolina C. Santos ,&nbsp;Simone A. Sampaio ,&nbsp;Anielle Pina-Costa ,&nbsp;Allison A. Fabri ,&nbsp;Vinícius Guerra-Campos ,&nbsp;Nieli R.C. Faria ,&nbsp;Ana Maria B. Filippis ,&nbsp;Patrícia Brasil ,&nbsp;Guilherme A. Calvet","doi":"10.1016/j.jcv.2023.105610","DOIUrl":"10.1016/j.jcv.2023.105610","url":null,"abstract":"<div><h3>Background</h3><p>Chikungunya can cause persistent chronic joint pain. Knowledge of the risk factors for disease progression is important for preventing and controlling complications. This study aimed to identify factors associated with chronic joint pain.</p></div><div><h3>Methods</h3><p>This prospective cohort study was conducted at a reference center in Rio de Janeiro. Men and women (aged ≥ 18 years) in the acute phase of Chikungunya were included. Clinical data and samples were collected over three months. Risk factors were evaluated using multivariate and logistic regression analyses.</p></div><div><h3>Results</h3><p>A total of 107 patients were followed up. The incidence rate of joint tenderness was 61.7 %. Female sex (adjusted odds ratio [AOR] 3.24, 95 % confidence interval [CI]:1.07–9.77), diarrhea (AOR 5.08, 95 % CI:1.55–16.67), severe joint pain (AOR 4.26, 95 % CI:1.06–17.06), and CHIKV real-time reverse transcription polymerase chain reaction positivity up to 5 days after the onset of symptoms in urine or saliva (AOR 4.56, 95 % CI:1.41–14.77) were identified as predictors of persistent chronic pain.</p></div><div><h3>Conclusions</h3><p>In a predominantly female population, musculoskeletal symptoms are not the sole determinant of chronic pain, and careful evaluation of CHIKV detection in alternative body fluids (such as saliva and urine) during the early phase of the disease is warranted.</p></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"169 ","pages":"Article 105610"},"PeriodicalIF":8.8,"publicationDate":"2023-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41202320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of varicella zoster virus DNA in blood from immunocompromised patients during the week preceding the onset of herpes zoster rash","authors":"Vincent Guiraud ,&nbsp;Henri Thévenet ,&nbsp;David Boutolleau","doi":"10.1016/j.jcv.2023.105609","DOIUrl":"10.1016/j.jcv.2023.105609","url":null,"abstract":"<div><h3>Objective</h3><p>To assess whether varicella zoster virus (VZV) DNA can be detected in blood before herpes zoster (HZ) rash onset.</p></div><div><h3>Method</h3><p>Monocentric retrospective study from January 2019 to March 2023 including patients with HZ and stored blood samples performed during the week preceding the onset of HZ rash. Blood samples were retrospectively analyzed for VZV DNA by quantitative PCR.</p></div><div><h3>Results</h3><p>Among the 138 patients with HZ during the study period, stored blood samples performed during the week preceding the onset of HZ rash were available for 13 of them. Twelve (92 %) patients were immunosuppressed, mostly due to solid organ transplantation (38 %), solid malignancy (31 %) or autoimmune disease (23 %). During the week preceding HZ onset, VZV DNA was detected in blood from 10 (77 %) patients, with a median value of 3.6 log (copies/mL) (IQR 3.3–3.9). At the time of HZ onset, all VZV PCR performed in available blood samples were positive.</p></div><div><h3>Conclusion</h3><p>Our findings demonstrates that VZV DNA can be commonly detected in blood from immunocompromised patients during the prodromal phase of HZ. Early screening of VZV DNA in blood from high-risk immunocompromised patients might improve HZ therapeutic management.</p></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"169 ","pages":"Article 105609"},"PeriodicalIF":8.8,"publicationDate":"2023-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41235771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}